A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

November 28, 2028

Study Completion Date

November 28, 2028

Conditions
Prostatic NeoplasmsAdenocarcinoma
Interventions
DRUG

JNJ-69086420

Participants will receive JNJ-69086420.

DRUG

JNJ-78278343

Participants will receive JNJ-78278343.

RADIATION

Stereotactic body radiation therapy

Participants will receive stereotactic body radiaition therapy.

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

32224

RECRUITING

Mayo Clinic in Florida, Jacksonville

44106

RECRUITING

Case Western Reserve University, Cleveland

55905

RECRUITING

Mayo Clinic Rochester, Rochester

60637

RECRUITING

University of Chicago, Chicago

68130

RECRUITING

XCancer Omaha / Urology Cancer Center, Omaha

70006

RECRUITING

East Jefferson General Hospital, Metairie

70112

RECRUITING

Tulane University Hospital & Clinics, New Orleans

84112

RECRUITING

University of Utah Huntsman Cancer Institute, Salt Lake City

91010

RECRUITING

City of Hope, Duarte

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY